Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 28


Trial watch - inhibiting PARP enzymes for anticancer therapy.

Sistigu A, Manic G, Obrist F, Vitale I.

Mol Cell Oncol. 2015 Jun 10;3(2):e1053594. doi: 10.1080/23723556.2015.1053594. eCollection 2016 Mar. Review.


New treatment option for ovarian cancer: PARP inhibitors.

Meehan RS, Chen AP.

Gynecol Oncol Res Pract. 2016 Feb 26;3:3. doi: 10.1186/s40661-016-0024-7. eCollection 2016. Review.


Profile of olaparib in the treatment of advanced ovarian cancer.

Chase DM, Patel S, Shields K.

Int J Womens Health. 2016 Apr 18;8:125-9. doi: 10.2147/IJWH.S55906. eCollection 2016. Review.


[PARP1 inhibitors: contemporary attempts at their use in anticancer therapy and future perspective].

Wiƛnik E, Ryksa M, Koter-Michalak M.

Postepy Hig Med Dosw (Online). 2016 Apr 13;70:280-94. Review. Polish.


PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives.

Sehouli J, Braicu EI, Chekerov R.

Geburtshilfe Frauenheilkd. 2016 Feb;76(2):164-169. Review.


Ovarian Cancer Molecular Stratification and Tumor Heterogeneity: A Necessity and a Challenge.

Symeonides S, Gourley C.

Front Oncol. 2015 Oct 21;5:229. doi: 10.3389/fonc.2015.00229. eCollection 2015. Review. No abstract available.


Effectiveness and safety of poly (ADP-ribose) polymerase inhibitors in cancer therapy: A systematic review and meta-analysis.

Bao Z, Cao C, Geng X, Tian B, Wu Y, Zhang C, Chen Z, Li W, Shen H, Ying S.

Oncotarget. 2016 Feb 16;7(7):7629-39. doi: 10.18632/oncotarget.5367. Review.


Olaparib in the management of ovarian cancer.

Bixel K, Hays JL.

Pharmgenomics Pers Med. 2015 Aug 7;8:127-35. doi: 10.2147/PGPM.S62809. eCollection 2015. Review.


PARP inhibitors and more.

Bose CK, Basu N.

J Turk Ger Gynecol Assoc. 2015 Jun 1;16(2):107-10. doi: 10.5152/jtgga.2015.15029. eCollection 2015. Review.


Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different?

Tan DS, Kaye SB.

Am Soc Clin Oncol Educ Book. 2015:114-21. doi: 10.14694/EdBook_AM.2015.35.114. Review.


Familial breast cancer - targeted therapy in secondary and tertiary prevention.

Kast K, Rhiem K.

Breast Care (Basel). 2015 Feb;10(1):27-31. doi: 10.1159/000380756. Review.


RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?

Downward J.

Clin Cancer Res. 2015 Apr 15;21(8):1802-9. doi: 10.1158/1078-0432.CCR-14-2180. Review.


Major clinical research advances in gynecologic cancer in 2014.

Suh DH, Lee KH, Kim K, Kang S, Kim JW.

J Gynecol Oncol. 2015 Apr;26(2):156-67. doi: 10.3802/jgo.2015.26.2.156. Review.


10(th) Congress on Lung Cancer-updates on clinical trials: goal.

Campelo RG, Massuti B, Mosquera J, Rosell R.

Transl Lung Cancer Res. 2014 Apr;3(2):66-9. doi: 10.3978/j.issn.2218-6751.2014.02.05. Review.


Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives.

Matsumoto K, Onda T, Yaegashi N.

Jpn J Clin Oncol. 2015 May;45(5):408-10. doi: 10.1093/jjco/hyv014. Epub 2015 Mar 11. Review.


Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy.

Walsh CS.

Gynecol Oncol. 2015 May;137(2):343-50. doi: 10.1016/j.ygyno.2015.02.017. Epub 2015 Feb 25. Review.


Major clinical research advances in gynecologic cancer in 2013.

Suh DH, Kim JW, Kang S, Kim HJ, Lee KH.

J Gynecol Oncol. 2014 Jul;25(3):236-48. doi: 10.3802/jgo.2014.25.3.236. Epub 2014 Jul 3. Review.


Personalised cancer medicine.

Jackson SE, Chester JD.

Int J Cancer. 2015 Jul 15;137(2):262-6. doi: 10.1002/ijc.28940. Epub 2014 May 12. Review.


PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.

Lee JM, Ledermann JA, Kohn EC.

Ann Oncol. 2014 Jan;25(1):32-40. doi: 10.1093/annonc/mdt384. Epub 2013 Nov 12. Review.


Targeted cancer therapy--are the days of systemic chemotherapy numbered?

Joo WD, Visintin I, Mor G.

Maturitas. 2013 Dec;76(4):308-14. doi: 10.1016/j.maturitas.2013.09.008. Epub 2013 Sep 20. Review.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk